Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
Taihei Ono, Satoshi Igawa, Shintaro Kurahayashi, Yuriko Okuma, Ai Sugimoto, Seiichiro Kusuhara, Takahiro Ozawa, Tomoya Fukui, Jiichiro Sasaki, Hisashi Mitsufuji, Masanori Yokoba, Masaru Kubota, Masato Katagiri, Katsuhiko Naoki
Topics & Concepts
GefitinibErlotinibMedicineInternal medicineLung cancerOncologyEpidermal growth factor receptorNeutrophil to lymphocyte rationon-small cell lung cancer (NSCLC)Progression-free survivalChemotherapyGastroenterologyCancerLymphocyteA549 cellLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Immunotherapy and Biomarkers